180 related articles for article (PubMed ID: 28801291)
1. [Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis].
Lei LZ; Xu YK; Hou MR; He MQ
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Aug; 37(8):1092-1097. PubMed ID: 28801291
[TBL] [Abstract][Full Text] [Related]
2. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
3. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
4. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
5. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
6. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
Wang L; Luo Y; Liu T; Deng M; Huang X
Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
[TBL] [Abstract][Full Text] [Related]
7. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
8. PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone.
Wen J; Tang T; Ji Y; Zhang Y
Front Oncol; 2022; 12():861928. PubMed ID: 35463349
[TBL] [Abstract][Full Text] [Related]
9. Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.
Lu YF; Zhang Q; Chen HY; Chen JY; Pan Y; Xu CC; Xu JX; Yu RS
Medicine (Baltimore); 2019 Jun; 98(26):e16289. PubMed ID: 31261602
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer.
Lin S; Yu X; Chen H; Chen Z; Yang Y
Int Urol Nephrol; 2023 Nov; 55(11):2685-2693. PubMed ID: 37523077
[TBL] [Abstract][Full Text] [Related]
11. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
[No Abstract] [Full Text] [Related]
12. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the performance of PI-RADS v2 in the non-academic setting.
Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
[TBL] [Abstract][Full Text] [Related]
14. Establishing a novel prediction model for improving the positive rate of prostate biopsy.
Tao T; Shen D; Yuan L; Zeng A; Xia K; Li B; Ge Q; Xiao J
Transl Androl Urol; 2020 Apr; 9(2):574-582. PubMed ID: 32420162
[TBL] [Abstract][Full Text] [Related]
15. Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
Lu YF; Zhang Q; Yao WG; Chen HY; Chen JY; Xu CC; Yu RS
Cancer Imaging; 2019 May; 19(1):26. PubMed ID: 31122297
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.
Massanova M; Vere R; Robertson S; Crocetto F; Barone B; Dutto L; Ahmad I; Underwood M; Salmond J; Patel A; Celentano G; Bhatt JR
Curr Urol; 2023 Sep; 17(3):147-152. PubMed ID: 37448611
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
[TBL] [Abstract][Full Text] [Related]
18. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
19. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
20. A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone.
Wei C; Pan P; Chen T; Zhang Y; Dai G; Tu J; Jiang Z; Zhao W; Shen J
Transl Androl Urol; 2021 Jun; 10(6):2435-2446. PubMed ID: 34295730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
